Rhythm Pharmaceuticals (RYTM) Non-Current Debt (2022 - 2026)
Rhythm Pharmaceuticals (RYTM) posted quarterly Non-Current Debt of $98.3 million for Q1 2026, down 8.89% year-over-year from $107.9 million in Q1 2025, and down 2.52% quarter-over-quarter from $100.9 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) Non-Current Debt (2022 - 2026) Analysis & Trends
Rhythm Pharmaceuticals (RYTM) has reported Non-Current Debt for 5 consecutive years, with $98.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 8.89% year-over-year to $98.3 million; the TTM figure through Mar 2026 stood at $98.3 million (down 8.89% YoY), while the FY2025 annual figure was $100.9 million, down 6.82% from the prior year.
- Non-Current Debt declined to $98.3 million in Q1 2026 per RYTM's latest filing, from $100.9 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $108.3 million in Q4 2024 and bottomed at $34.3 million in Q2 2022.
- Historically, Non-Current Debt has averaged $93.1 million across 5 years, with a median of $103.4 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Debt gained 2.0% — and 2026, when it dropped 8.89%.
- Rhythm Pharmaceuticals' Non-Current Debt stood at $73.0 million in 2022, then surged by 45.48% to $106.1 million in 2023, then gained by 2.0% to $108.3 million in 2024, then retreated by 6.82% to $100.9 million in 2025, then slipped by 2.52% to $98.3 million in 2026.
- Business Quant data shows RYTM's Non-Current Debt at $98.3 million in Q1 2026, $100.9 million in Q4 2025, and $103.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Rhythm Pharmaceuticals | 7.95 Bn | 7.62 Bn | 62.32 Mn | 93.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 93.40 Mn |
| Mar 31, 2026 | 98.34 Mn |
| Dec 31, 2025 | 100.89 Mn |
| Sep 30, 2025 | 103.41 Mn |
| Jun 30, 2025 | 106.01 Mn |
| Mar 31, 2025 | 107.93 Mn |
| Dec 31, 2024 | 108.27 Mn |
| Dec 31, 2023 | 106.14 Mn |
| Sep 30, 2022 | 72.96 Mn |
| Jun 30, 2022 | 34.27 Mn |